These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

300 related articles for article (PubMed ID: 37061987)

  • 21. The FDA Oncology Center of Excellence and precision medicine.
    Goldberg KB; Blumenthal GM; McKee AE; Pazdur R
    Exp Biol Med (Maywood); 2018 Feb; 243(3):308-312. PubMed ID: 29105511
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Comprehensive analysis of potential immunotherapy genomic biomarkers in 1000 Chinese patients with cancer.
    Zang YS; Dai C; Xu X; Cai X; Wang G; Wei J; Wu A; Sun W; Jiao S; Xu Q
    Cancer Med; 2019 Aug; 8(10):4699-4708. PubMed ID: 31270941
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The tumor-agnostic treatment for patients with solid tumors: a position paper on behalf of the AIOM- SIAPEC/IAP-SIBioC-SIF Italian Scientific Societies.
    Russo A; Incorvaia L; Malapelle U; Del Re M; Capoluongo E; Vincenzi B; Chiari R; Cortesi L; Danesi R; Florena AM; Fontanini G; Gori S; Marchetti A; Normanno N; Pinto C; Sangiolo D; Silvestris N; Tagliaferri P; Tallini G; Cinieri S; Beretta GD
    Crit Rev Oncol Hematol; 2021 Sep; 165():103436. PubMed ID: 34371157
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Histology-agnostic drug development - considering issues beyond the tissue.
    Pestana RC; Sen S; Hobbs BP; Hong DS
    Nat Rev Clin Oncol; 2020 Sep; 17(9):555-568. PubMed ID: 32528101
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Application of histology-agnostic treatments in metastatic colorectal cancer.
    Sartore-Bianchi A; Agostara AG; Patelli G; Mauri G; Pizzutilo EG; Siena S
    Dig Liver Dis; 2022 Oct; 54(10):1291-1303. PubMed ID: 35701319
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Use of pembrolizumab among older adults with cancer in the United States, before and after FDA approval of its tumor-agnostic indication.
    Hong YD; Enewold L; Halpern MT; Zeruto C; Mariotto AB
    Pharmacoepidemiol Drug Saf; 2024 Jan; 33(1):e5745. PubMed ID: 38156547
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Evolution of the Targeted Therapy Landscape for Cholangiocarcinoma: Is Cholangiocarcinoma the 'NSCLC' of GI Oncology?
    Gupta A; Kurzrock R; Adashek JJ
    Cancers (Basel); 2023 Mar; 15(5):. PubMed ID: 36900367
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pembrolizumab in microsatellite instability high or mismatch repair deficient cancers: updated analysis from the phase II KEYNOTE-158 study.
    Maio M; Ascierto PA; Manzyuk L; Motola-Kuba D; Penel N; Cassier PA; Bariani GM; De Jesus Acosta A; Doi T; Longo F; Miller WH; Oh DY; Gottfried M; Xu L; Jin F; Norwood K; Marabelle A
    Ann Oncol; 2022 Sep; 33(9):929-938. PubMed ID: 35680043
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pancreatic cancer biomarkers: A pathway to advance in personalized treatment selection.
    Brozos-Vázquez E; Toledano-Fonseca M; Costa-Fraga N; García-Ortiz MV; Díaz-Lagares Á; Rodríguez-Ariza A; Aranda E; López-López R
    Cancer Treat Rev; 2024 Apr; 125():102719. PubMed ID: 38490088
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Rare cancer, rare alteration: the case of NTRK fusions in biliary tract cancers.
    Boilève A; Verlingue L; Hollebecque A; Boige V; Ducreux M; Malka D
    Expert Opin Investig Drugs; 2021 Apr; 30(4):401-409. PubMed ID: 33641556
    [No Abstract]   [Full Text] [Related]  

  • 31. Identification and Utilization of Biomarkers to Predict Response to Immune Checkpoint Inhibitors.
    Gjoerup O; Brown CA; Ross JS; Huang RSP; Schrock A; Creeden J; Fabrizio D; Tolba K
    AAPS J; 2020 Oct; 22(6):132. PubMed ID: 33057937
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Tumor-Agnostic Treatment for Cancer: When How is Better than Where.
    Lavacchi D; Roviello G; D'Angelo A
    Clin Drug Investig; 2020 Jun; 40(6):519-527. PubMed ID: 32307639
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A scoping review and meta-analysis on the prevalence of pan-tumour biomarkers (dMMR, MSI, high TMB) in different solid tumours.
    Kang YJ; O'Haire S; Franchini F; IJzerman M; Zalcberg J; Macrae F; Canfell K; Steinberg J
    Sci Rep; 2022 Nov; 12(1):20495. PubMed ID: 36443366
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Agnostic Administration of Targeted Anticancer Drugs: Looking for a Balance between Hype and Caution.
    Aleksakhina SN; Ivantsov AO; Imyanitov EN
    Int J Mol Sci; 2024 Apr; 25(7):. PubMed ID: 38612902
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Controversy of tissue-agnostic approvals in immunotherapy and targeted therapy.
    Bose CK
    Med Oncol; 2022 Apr; 39(5):67. PubMed ID: 35478274
    [TBL] [Abstract][Full Text] [Related]  

  • 36. AACR Project GENIE: 100,000 Cases and Beyond.
    Pugh TJ; Bell JL; Bruce JP; Doherty GJ; Galvin M; Green MF; Hunter-Zinck H; Kumari P; Lenoue-Newton ML; Li MM; Lindsay J; Mazor T; Ovalle A; Sammut SJ; Schultz N; Yu TV; Sweeney SM; Bernard B;
    Cancer Discov; 2022 Sep; 12(9):2044-2057. PubMed ID: 35819403
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Combination of AKT1 and CDH1 mutations predicts primary resistance to immunotherapy in dMMR/MSI-H gastrointestinal cancer.
    Wang Z; Zhang Q; Qi C; Bai Y; Zhao F; Chen H; Li Z; Wang X; Chen M; Gong J; Peng Z; Zhang X; Cai J; Chen S; Zhao X; Shen L; Li J
    J Immunother Cancer; 2022 Jun; 10(6):. PubMed ID: 35705314
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Microsatellite instability and immune checkpoint inhibitors: toward precision medicine against gastrointestinal and hepatobiliary cancers.
    Eso Y; Shimizu T; Takeda H; Takai A; Marusawa H
    J Gastroenterol; 2020 Jan; 55(1):15-26. PubMed ID: 31494725
    [TBL] [Abstract][Full Text] [Related]  

  • 39. AACR Project GENIE: Powering Precision Medicine through an International Consortium.
    AACR Project GENIE Consortium
    Cancer Discov; 2017 Aug; 7(8):818-831. PubMed ID: 28572459
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Precision Medicine in Oncology: A Review of Multi-Tumor Actionable Molecular Targets with an Emphasis on Non-Small Cell Lung Cancer.
    Stein MK; Oluoha O; Patel K; VanderWalde A
    J Pers Med; 2021 Jun; 11(6):. PubMed ID: 34198738
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.